These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 19859891)

  • 1. [Fifteen years history of Parkinson's disease in Spain (1963-1977). A personal recollection].
    Giménez-Roldán S
    Rev Neurol; 2009 Nov 1-15; 49(9):490-5. PubMed ID: 19859891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fifteen years history of Parkinson's disease in Spain. The dark years].
    de Yébenes JG
    Rev Neurol; 2009 Nov 1-15; 49(9):449-50. PubMed ID: 19859883
    [No Abstract]   [Full Text] [Related]  

  • 3. The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
    Fahn S
    Mov Disord; 2015 Jan; 30(1):4-18. PubMed ID: 25491387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chapter 33: the history of movement disorders.
    Lanska DJ
    Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survey on general knowledge on Parkinson's disease in patients with Parkinson's disease and current clinical practice for Parkinson's disease among general neurologists from Southwest China.
    Li J; Chen D; Song W; Chen K; Cao B; Huang R; Yang R; Shang H
    Clin Neurol Neurosurg; 2014 Mar; 118():16-20. PubMed ID: 24529223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Levodopa in the treatment of Parkinson's disease: myths and realties].
    Luquin MR; García-Ruiz PJ; Martí MJ; Rojo A; Vela L; Grandas FJ; Bravo-Utrera M; Burguera JA; Chacón JR; Campos-Arillo VM; Durán-Herrera C; Fernández-García JM; García-Ramos R; Gómez-Esteban JC; Gutierrez J; Juni J; Mata M; Martínez-Castrillo JC; Olivares J; Ribacoba-Montero R; Santos-García D; Sierra M; Valero-Merino C
    Rev Neurol; 2012 Dec; 55(11):669-88. PubMed ID: 23172094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Young onset Parkinson's disease.
    Quinn N; Critchley P; Marsden CD
    Mov Disord; 1987; 2(2):73-91. PubMed ID: 3504266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rating scale and functional prognosis of Parkinson's disease].
    Nakano I; Fujimoto K
    Nihon Rinsho; 2000 Oct; 58(10):2132-8. PubMed ID: 11068460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hallucinations in Parkinson disease in the prelevodopa era.
    Fénelon G; Goetz CG; Karenberg A
    Neurology; 2006 Jan; 66(1):93-8. PubMed ID: 16401853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unresolved issues relating to the shaking palsy on the celebration of James Parkinson's 250th birthday.
    Lees AJ
    Mov Disord; 2007 Sep; 22 Suppl 17():S327-34. PubMed ID: 18175393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential modulation of STN-cortical and cortico-muscular coherence by movement and levodopa in Parkinson's disease.
    Hirschmann J; Özkurt TE; Butz M; Homburger M; Elben S; Hartmann CJ; Vesper J; Wojtecki L; Schnitzler A
    Neuroimage; 2013 Mar; 68():203-13. PubMed ID: 23247184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opposite motor effects of pallidal stimulation in Parkinson's disease.
    Krack P; Pollak P; Limousin P; Hoffmann D; Benazzouz A; Le Bas JF; Koudsie A; Benabid AL
    Ann Neurol; 1998 Feb; 43(2):180-92. PubMed ID: 9485059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
    J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cortical plasticity and levodopa-induced dyskinesias in Parkinson's disease: Connecting the dots in a multicomponent network.
    Rajan R; Popa T; Quartarone A; Ghilardi MF; Kishore A
    Clin Neurophysiol; 2017 Jun; 128(6):992-999. PubMed ID: 28454042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Professor Oleh Hornykiewicz on the occasion of his 75th birthday and the first L-DOPA treatment of Parkinson's disease 40 years ago.
    Kobinger W
    Wien Klin Wochenschr; 2001 Nov; 113(22):847-50. PubMed ID: 11762120
    [No Abstract]   [Full Text] [Related]  

  • 20. A brief history of parkinsonism.
    Duvoisin RC
    Neurol Clin; 1992 May; 10(2):301-16. PubMed ID: 1584174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.